Dataset Information


Clinical and Pathologic Response of the Primary Tumor in Women Receiving Neoadjuvant Docetaxel-Capecitabine (+/- Trastuzumab) Chemotherapy

ABSTRACT: Results: In subjects who completed treatment and surgery, the pCR and near-complete response rates were 15.8% in HER2-negative and 50% in HER2-positive subjects. When stratified by genomic subtype, subjects of the HER2-enriched subtype had the best response (66.7%), the luminal A (11%) and B (4.8%) subtypes the poorest. Of 147 patients tested for p53 mutations using the AmpliChip test, 78 variants were detected; 55 were missense. The response rate among TP53 mutated patients was 30%, significantly higher than the rate in TP53 wild-type patients (10%, P = .0032). Concordance between AmpliChip mutation status versus IHC staining was 65%, with AmpliChip status being predictive of response and IHC status being not being predictive. Conclusion: Capecitabine plus docetaxel in HER2-negative subjects, and with trastuzumab in HER2-positive subjects, provided a good response rate with fewer cycles. p53 mutational analysis using the AmpliChip p53 assay, and genomic subtyping using the PAM50 assay, were promising predictive tests of response. reference x sample

ORGANISM(S): Homo sapiens  

SUBMITTER: Charles Perou   Charles M Perou  Lin Wu  Stepan Gluck 

PROVIDER: E-GEOD-22358 | ArrayExpress | 2011-03-18



altmetric image


TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.

Glück Stefan S   Ross Jeffrey S JS   Royce Melanie M   McKenna Edward F EF   Perou Charles M CM   Avisar Eli E   Wu Lin L  

Breast cancer research and treatment 20110304 3

To determine rates of pathologic complete response (pCR) and near-complete response (npCR) in operable early-stage breast cancer using neoadjuvant capecitabine plus docetaxel, with or without trastuzumab, and investigate biomarkers of pathologic response. Women with operable early-stage breast cancer were enrolled in a multicenter study of neoadjuvant therapy for four 21-day cycles with capecitabine 825 mg/m(2) plus docetaxel 75 mg/m(2) if human epidermal growth factor receptor 2 (HER2)-negative  ...[more]

Similar Datasets

2012-01-13 | E-GEOD-22226 | ArrayExpress
2011-03-18 | GSE22358 | GEO
2014-06-30 | E-GEOD-52783 | ArrayExpress
2010-06-24 | E-GEOD-10886 | ArrayExpress
2015-01-21 | E-GEOD-48073 | ArrayExpress
2008-06-12 | E-GEOD-3178 | ArrayExpress
2013-09-03 | E-GEOD-41118 | ArrayExpress
2014-07-29 | E-GEOD-41119 | ArrayExpress
2011-08-14 | E-GEOD-27101 | ArrayExpress
2013-06-25 | E-GEOD-34412 | ArrayExpress